Natera CEO Steven Chapman Sells Shares Under Pre-Planned Trading Plan
Steven Leonard Chapman, CEO and President of Natera (NASDAQ:NTRA), sold 1,698 shares on Sept. 1, 2026, for a total value of $545,000 under an amended Rule 10b5-1 trading plan established in March 2026 and originally adopted in December 2023. The transaction was disclosed via SEC Form 4 filing and is considered routine rather than indicative of any internal concerns at the company. Following this sale, Chapman holds approximately 98,199 shares directly, representing about 0.06% ownership in Natera’s total equity. Additionally, he retains derivative securities tied to the firm's performance. The stock price on the day of the transaction was $320.99 per share, and over the past year through Sept. 1, it had delivered a strong return of nearly 91%. Natera remains a major player in molecular diagnostics with a market cap of $52.1 billion despite reporting net losses for the trailing twelve months (TTM) at -$192.3 million. The company continues to grow its revenue and expand into global markets through diagnostic services like prenatal, carrier, and single-gene disorder testing.
Tickers: $NTRA
Topics: CEO Rule 10b5-1 plan SEC filing stock sale